Celgene Corporation (CELG): Today's Featured Health Care Winner

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

Celgene Corporation ( CELG) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day up 0.4%. By the end of trading, Celgene Corporation rose $1.43 (1.2%) to $124.91 on average volume. Throughout the day, 4,085,774 shares of Celgene Corporation exchanged hands as compared to its average daily volume of 3,242,400 shares. The stock ranged in a price between $120.35-$125.05 after having opened the day at $124.56 as compared to the previous trading day's close of $123.48. Other companies within the Health Care sector that increased today were: EnteroMedics ( ETRM), up 22.1%, Vanda Pharmaceuticals ( VNDA), up 19.6%, TrovaGene ( TROV), up 11.9% and Edap TMS ( EDAP), up 10.9%.
  • EXCLUSIVE OFFER: Jim Cramer's Protege, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Celgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of various therapies to treat cancer and immune-inflammatory related diseases in the United States, Europe, and other countries. Celgene Corporation has a market cap of $54.1 billion and is part of the drugs industry. The company has a P/E ratio of 39.4, above the S&P 500 P/E ratio of 17.7. Shares are up 65.2% year to date as of the close of trading on Thursday. Currently there are 21 analysts that rate Celgene Corporation a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Celgene Corporation as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, good cash flow from operations, expanding profit margins and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

On the negative front, Senesco Technologies ( SNT), down 64.8%, Senesco Technologies ( SNTI), down 64.8%, Prima Biomed ( PBMD), down 15.5% and AdCare Health Systems ( ADK), down 12.4% , were all laggards within the health care sector with Catamaran ( CTRX) being today's health care sector laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.